Publicação científica trimestral do CREMERJ

91 Varicela e herpes-zóster Omar Lupi Med. Ciên. e Arte , Rio de Janeiro, v.1, n.1, p.84-91, jan-mar 2022 5. Friesen KJ, Alessi-Severini S, Chateau D, Falk J, Bugden S 2016. The changing landscape of antiviral treatment of herpes zoster: a 17-year population-based cohort study. ClinicoEconomics and Outcomes Research: CEOR. 8:207-214. 6. Guidelines on the Treatment of Skin and Oral HIV–Associated Conditions in Children and Adults 2014. Geneva: World Health Organization. 7. Jeon YH 2015. Herpes Zoster and Postherpetic Neuralgia: Practical Consideration for Prevention and Treatment. Korean J Pain. 28(3):177-84. 8. Johnson RW, Alvarez-Pasquin MJ, Bijl M, Franco E, Gaillat J, Clara JG et al. 2015. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Therapeutic Advances in Vaccines, 3 (4), 109–120. 9. Marin M, Yawn BP, Hales CM, Wollan PC, Bialek SR, Zhang J, Kurland MJ, Harpaz R 2015. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Hum Vaccin Immunother.;11(5):1157-64. 10. “Matrix é Aqui”. Ser Médico (Cremesp) Jul/Ago/Set/2009; n. 48. p. 14-15. 11. McCrary ML et al. Varicella Zoster Virus (CME). J. Am. Acad. Dermatology. July/1999; 41(1)-1-16. 12. Nagasako EM et al. Rash severity in herpes zoster: correlates and relationship to postherpetic neuralgia. June/2002; 46 (6)-834-9. 13. Oxman MN et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Eng. J. Med. Jun/2005; 352, 2271-84. 14. Préaud E, Uhart M, Böhm K, Aidelsburger P, Anger D, Bianic F, Largeron N 2015 Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany. Hum Vaccin Immunother.;11(4):884-96. 15. Rice G et al. Gabapentine in the treatment of postherpetic neuralgia. Pain. 2001; 94-215-24. 16. Rook A et al. Herpes-zoster. Textbook of dermatology. 4th edition. Blackwell Editions.1986; Vol.1. p. 680-85. 17. Sampaio S, Rivitti EA. Herpes-zoster. 3. ed. Dermatologia. Artes Médicas. 2007; 560-1. 18. Shuanglin H et al. Gene transfer of glutamic acid decarboxylase reduces neurophatic pain. Annals of Neurology. June/2005; 57(6) 914-18. 19. Teixeira MJ et al. Iontoforese de vincristina para o tratamento de neuralgia pós-herpética. Arq. Brasil. de Neuroc. 1993; (12)223-34. 20. Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E et al. 2012 Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. J Intern Med. 271(5):510-20.